Gastrointestinal Cancer | Specialty

Novel Treatment Strategies Explored in Pancreatic Cancer

February 11th 2014

Optimizing Treatment of Advanced Pancreatic Cancer

February 11th 2014

Cost Effectiveness of Therapies in Pancreatic Cancer

February 11th 2014

Gemcitabine/Nab-Paclitaxel in Advanced Pancreatic Cancer

February 11th 2014

Introduction: FOLFIRINOX in Metastatic Pancreatic Cancer

February 11th 2014

Dr. Ramanathan on an Analysis of the MPACT Trial

February 11th 2014

Ramesh K. Ramanathan, MD, medical director, Clinical Trials Program, Virginia G. Piper Cancer Center, describes the results from an analysis of metabolic response by positron emission tomography (PET) compared with tumor response by computed tomography (CT) from the phase III MPACT trial.

Hopes Revived for Targeting the "Undruggable" RAS Family

February 11th 2014

The members of the RAS oncogene family are central cogs in many different cell-signaling pathways, coordinate a variety of important cellular processes, and are highly mutated in a number of different cancers, including several with extremely poor prognosis.

Dr. Kunz on Treatment Options for Pancreatic NETs

February 10th 2014

Pamela L. Kunz, MD, assistant professor of medicine, Oncology, Stanford University Medical Center, discusses current and future treatment options for patients with neuroendocrine tumors (NETs).

ALK and ROS1 Lung Cancer Oncogenes May Also Drive Colorectal Cancer

February 7th 2014

Gene rearrangements ALK and ROS1 that are known to drive subsets of lung cancer are also present in colorectal cancer according to a recent study in Molecular Cancer Research.

Dr. Peeters on KRAS/NRAS Mutations in mCRC

February 6th 2014

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses an analysis of RAS mutations in the phase III study 20050181, which compared panitumumab plus FOLFIRI versus FOLFIRI for second-line treatment of mCRC

Robert McCormack Explains the CellSearch CTC Test

February 5th 2014

Robert McCormack, PhD, head, Technology Innovation, Janssen Diagnostics, LLC, explains the circulating tumor cell test CellSearch.

Cytoreductive Surgery and HIPEC for Peritoneal Carcinomatosis

February 5th 2014

The management of patients with malignant peritoneal surface disease (PSD) commonly known as "carcinomatosis" continues to evolve.

Pancreatic Cancer Starkly Illustrates Challenges of Developing Targeted Therapies

February 4th 2014

A recent study determined that it would take 6.7 years on average to enroll enough patients with pancreatic cancer for the trials that opened in 2011-a tall order considering that the 5-year relative survival rate for those diagnosed with pancreatic ductal adenocarcinoma is only 6%.

Dr. Abou-Alfa on LY2157299 in HCC

January 28th 2014

Ghassan K. Abou-Alfa, MD, discusses the phase II study of a novel transforming growth factor-beta (TGF-β1) receptor I kinase inhibitor, LY2157299 monohydrate, in patients with advanced hepatocellular carcinoma (HCC), which was presented at the 2014 Gastrointestinal Cancers Symposium.

Examining the Role of Vitamin D in Colorectal Cancer Survival

January 27th 2014

Epidemiologic and scientific research indicates that diet and other lifestyle factors have a significant influence on the risk of developing colorectal cancer.

Dr. Bordonaro on First-Line Treatment Options for mCRC

January 24th 2014

Roberto Bordonaro, MD, discusses first-line treatment options for advanced colorectal cancer (CRC).

Dr. Fakih on RAS Mutations in Colon Cancer

January 22nd 2014

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses extended RAS mutations in colon cancer.

RAS Mutational Analyses in mCRC Trials Highlight Need to 'Think Beyond KRAS'

January 20th 2014

Studies presented at the 2014 GI Cancers Symposium emphasized the need for full RAS mutational analyses in the management of metastatic colorectal cancer prior to initiating treatment with anti-EGFR monoclonal antibodies.

Novel Targeted Agent Leads to Survival Benefit in HCC

January 20th 2014

Treatment with LY2157299 led to significant reductions in a prespecified biomarker that correlated with increased time to progression and overall survival in patients with advanced hepatocellular carcinoma.

Hedgehog Inhibitor Regimen Active in Advanced Pancreatic Cancer

January 20th 2014

Add-on treatment with the hedgehog pathway inhibitor vismodegib demonstrated encouraging activity in patients with untreated metastatic pancreatic ductal adenocarcinoma.